Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose ribavirin in chronic hepatitis C genotype 3 patients without week 4 rapid virologic response
2008-000328-16Phase 4Completed
- Sponsor
- Hospital Universitario Fundación Alcorcón
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ribavirin in hepatitis C virus infection (2 arms), sponsored by Hospital Universitario Fundación Alcorcón. Primary endpoint: Sustained virologic response. Started Mar 2008; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-000328-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000328-16.